Genetic modulation of hypoxia induced gene expression and angiogenesis: relevance to brain tumors.

Angiogenesis is required for the development and biologic progression of infiltrative astrocytomas and takes the form of "microvascular hyperplasia" in glioblastoma multiforme, the most malignant astrocytoma. This pathologic term refers to an abnormal vascular proliferation that is often associated with necrosis and likely originates in hypoxic zones. Both the physiologic response to hypoxia and genetic alterations contribute to this process. The presence of hypoxic regions within an expanding tumor mass leads to upregulation of pro-angiogenic factors, such as vascular endothelial growth factor (VEGF), through increased activity of the transcriptional complex HIF-1 (hypoxia-inducible factor-1). HIF-1 mediated gene expression may be directly or indirectly modulated by alterations in oncogenes/tumor suppressor genes that occur during astrocytoma development, including PTEN, TP53, p16(CDKN2A), p14ARF, EGFR, and PDGFR. Genetic alterations are also believed to influence the HIF-independent expression of pro- and anti- angiogenic factors, such as basic fibroblast growth factor (bFGF) and thrombospondin-1 (TSP-1), respectively. Thus, genetic events that occur during the progression of infiltrating astrocytomas promote angiogenesis, both by modulating hypoxia induced gene expression and by regulating of pro- and anti- angiogenic factors.

[1]  L. Neckers,et al.  Stabilization of wild-type p53 by hypoxia-inducible factor 1α , 1998, Nature.

[2]  K. Plate,et al.  Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. , 1995, Cancer research.

[3]  A. Harris,et al.  Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Mukhopadhyay,et al.  Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation , 1995, Nature.

[5]  K. Herrup,et al.  The essential role of Cited2, a negative regulator for HIF-1α, in heart development and neurulation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Erwin G. Van Meir,et al.  Generation of bidirectional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells , 2001, Gene Therapy.

[7]  W. Kaelin,et al.  Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. , 1999, Science.

[8]  T. Nose,et al.  Concentration of vascular endothelial growth factor in the serum and tumor tissue of brain tumor patients. , 1996, Cancer research.

[9]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[10]  K. Plate,et al.  Up-Regulation of Vascular Endothelial Growth Factor in Stromal Cells of Hemangioblastomas Is Correlated with Up-Regulation of the Transcription Factor HRF/HIF-2α , 1998 .

[11]  G. Semenza,et al.  FIH-1: a novel protein that interacts with HIF-1alpha and VHL to mediate repression of HIF-1 transcriptional activity. , 2001 .

[12]  Andrew L. Kung,et al.  Suppression of tumor growth through disruption of hypoxia-inducible transcription , 2000, Nature Medicine.

[13]  A. Koong,et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.

[14]  A. Giaccia,et al.  Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. , 2001, Cancer research.

[15]  R. Strausberg,et al.  Transcriptional response to hypoxia in human tumors. , 2001, Journal of the National Cancer Institute.

[16]  Christopher J Schofield,et al.  Hypoxia-inducible Factor (HIF) Asparagine Hydroxylase Is Identical to Factor Inhibiting HIF (FIH) and Is Related to the Cupin Structural Family* , 2002, The Journal of Biological Chemistry.

[17]  D. Peet,et al.  Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.

[18]  H. Nishi,et al.  Early Growth Response-1 gene mediates up-regulation of epidermal growth factor receptor expression during hypoxia. , 2002, Cancer research.

[19]  G. Semenza,et al.  Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. , 2000, Cancer.

[20]  K. Kinzler,et al.  Combination bacteriolytic therapy for the treatment of experimental tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Louis,et al.  Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis , 1993, Brain pathology.

[22]  Erwin G. Van Meir,et al.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.

[23]  L. Ellis,et al.  Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. , 1998, Cancer research.

[24]  A. Szalay,et al.  The p14ARF Tumor Suppressor Protein Facilitates Nucleolar Sequestration of Hypoxia-inducible Factor-1α (HIF-1α) and Inhibits HIF-1-mediated Transcription* , 2001, The Journal of Biological Chemistry.

[25]  G. Semenza,et al.  Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[26]  G. Semenza,et al.  Dimerization, DNA Binding, and Transactivation Properties of Hypoxia-inducible Factor 1* , 1996, The Journal of Biological Chemistry.

[27]  D. Carbone,et al.  Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. , 1998, Blood.

[28]  D. Mukhopadhyay,et al.  Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. , 1995, Cancer research.

[29]  Mennel Hd,et al.  Mechanisms of angiogenesis in the brain , 2000 .

[30]  M. Nagao,et al.  Activation of Hypoxia-inducible Factor-1; Definition of Regulatory Domains within the α Subunit* , 1997, The Journal of Biological Chemistry.

[31]  P. Ratcliffe,et al.  Activation of the HIF pathway in cancer. , 2001, Current opinion in genetics & development.

[32]  D. Hanahan,et al.  Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. , 1997, Cancer research.

[33]  G. Fulci,et al.  p53 and Brain Tumors: From Gene Mutations to Gene Therapy , 1998, Brain pathology.

[34]  B. Vogelstein,et al.  Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Michael I. Wilson,et al.  C. elegans EGL-9 and Mammalian Homologs Define a Family of Dioxygenases that Regulate HIF by Prolyl Hydroxylation , 2001, Cell.

[36]  Erwin G. Van Meir Cytokines and tumors of the central nervous system , 1995, Glia.

[37]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[38]  Erwin G. Van Meir,et al.  Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. , 2001, The American journal of pathology.

[39]  E. Oldfield,et al.  Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. , 1992, Cancer research.

[40]  Yuichi Makino,et al.  Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway* , 1999, The Journal of Biological Chemistry.

[41]  P. Carmeliet,et al.  Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice , 2002, Nature Medicine.

[42]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[43]  G. Semenza,et al.  Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. , 1999, Developmental biology.

[44]  Erwin G. Van Meir,et al.  Thrombospondins and tumor angiogenesis. , 2001, Trends in molecular medicine.

[45]  E. Manseau,et al.  Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. , 2001, The American journal of pathology.

[46]  Erwin G. Van Meir,et al.  p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma , 2000, Oncogene.

[47]  Yusuke Nakamura,et al.  A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis , 1997, Oncogene.

[48]  W. Cavenee,et al.  Induction of vascular endothelial growth factor expression in endothelial cells by platelet-derived growth factor through the activation of phosphatidylinositol 3-kinase. , 1999, Cancer research.

[49]  C. Heldin,et al.  Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. , 1992, Cancer research.

[50]  G. Semenza,et al.  Hypoxia-inducible factor 1: oxygen homeostasis and disease pathophysiology. , 2001, Trends in molecular medicine.

[51]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[52]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[53]  J. Gleadle,et al.  Induction of hypoxia-inducible factor-1, erythropoietin, vascular endothelial growth factor, and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase. , 1997, Blood.

[54]  T. Mikkelsen,et al.  Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. , 1996, Cancer research.

[55]  S. Sakaki,et al.  Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. , 1999, Cancer research.

[56]  D. O’Rourke,et al.  Epidermal Growth Factor Receptor Transcriptionally UpRegulates Vascular Endothelial Growth Factor Expression in Human Glioblastoma Cells via a Pathway Involving Phosphatidylinositol 3 *-Kinase and Distinct from That Induced by Hypoxia 1 , 2000 .

[57]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[58]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[59]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[60]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[61]  G. Reifenberger,et al.  CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. , 1994, Cancer research.

[62]  G. Semenza,et al.  Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway* , 2002, The Journal of Biological Chemistry.

[63]  Michael P. Myers,et al.  PTEN controls tumor-induced angiogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  H. Dvorak,et al.  VPF/VEGF and the angiogenic response. , 2000, Seminars in perinatology.

[65]  F. Zindy,et al.  The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Christopher J. Robinson,et al.  The splice variants of vascular endothelial growth factor (VEGF) and their receptors. , 2001, Journal of cell science.

[67]  J. Folkman What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[68]  G. Semenza,et al.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.

[69]  L. Poellinger,et al.  Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of theCBP/p300 coactivator by the hypoxia‐induciblefactor‐1α , 1998, The EMBO journal.

[70]  A. Giaccia,et al.  Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. , 1997, Blood.

[71]  P. Vogt,et al.  Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[72]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[73]  Yoichi Taya,et al.  Regulation of p53 by Hypoxia: Dissociation of Transcriptional Repression and Apoptosis from p53-Dependent Transactivation , 2001, Molecular and Cellular Biology.

[74]  Till Acker,et al.  Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration , 2001, Nature Genetics.

[75]  M. Gassmann,et al.  Up-regulation of hypoxia-inducible factor-1alpha is not sufficient for hypoxic/anoxic p53 induction. , 1998, Cancer research.

[76]  T. Fojo,et al.  p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription* , 1998, The Journal of Biological Chemistry.

[77]  P. Wesseling,et al.  Early and Extensive Contribution of Pericytes/Vascular Smooth Muscle Cells to Microvascular Proliferation in Glioblastoma Multiforme: An Immuno‐light and Immuno‐electron Microscopic Study , 1995, Journal of neuropathology and experimental neurology.

[78]  Erwin G. Van Meir,et al.  Upregulation of Interleukin 8 by Oxygen-deprived Cells in Glioblastoma Suggests a Role in Leukocyte Activation, Chemotaxis, and Angiogenesis , 1997, The Journal of experimental medicine.

[79]  M. Lopes Angiogenesis in brain tumors , 2003, Microscopy research and technique.

[80]  Erwin G. Van Meir,et al.  Genetic instability leads to loss of both p53 alleles in a human glioblastoma , 1998, Oncogene.

[81]  Erwin G. Van Meir,et al.  Thrombospondin-1 Is Downregulated by Anoxia and Suppresses Tumorigenicity of Human Glioblastoma Cells , 2000, The Journal of experimental medicine.

[82]  R. Kerbel Tumor angiogenesis: past, present and the near future. , 2000, Carcinogenesis.

[83]  W. Cavenee,et al.  Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. , 2001, Cancer research.

[84]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[85]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[86]  L. Huang,et al.  Regulation of hypoxia-inducible factor 1α is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway , 1998 .

[87]  Erwin G. Van Meir,et al.  Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma , 1999, Oncogene.

[88]  W Arap,et al.  Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. , 1997, Cancer research.

[89]  G. Semenza,et al.  In vivo expression of mRNAs encoding hypoxia-inducible factor 1. , 1996, Biochemical and biophysical research communications.

[90]  G. Semenza,et al.  V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. , 1997, Cancer research.

[91]  T. Hunter,et al.  Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[92]  A. Harris,et al.  Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway , 2001, British Journal of Cancer.

[93]  Charles J. Sherr,et al.  Nucleolar Arf sequesters Mdm2 and activates p53 , 1999, Nature Cell Biology.

[94]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[95]  M. Ivan,et al.  The von Hippel-Lindau tumor suppressor protein. , 2001, Current opinion in genetics & development.

[96]  K. Dameron,et al.  Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.

[97]  Dian Feng,et al.  Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor , 2000, Laboratory Investigation.

[98]  M R Paradis,et al.  Tumors of the central nervous system. , 1998, The Veterinary clinics of North America. Equine practice.

[99]  Erwin G. Van Meir,et al.  Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. , 2003, The American journal of pathology.

[100]  J. Schlessinger Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[101]  D. Peet,et al.  FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. , 2002, Genes & development.

[102]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[103]  Yuichi Makino,et al.  Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression , 2001, Nature.

[104]  Till Acker,et al.  Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function , 2000, Oncogene.

[105]  L. Cantley,et al.  New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[106]  Erwin G. Van Meir,et al.  Analysis of the p53 gene and its expression in human glioblastoma cells. , 1994, Cancer research.

[107]  S. Bhattacharya,et al.  Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. , 1999, Genes & development.

[108]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[109]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[110]  G. Semenza,et al.  HER2 (neu) Signaling Increases the Rate of Hypoxia-Inducible Factor 1α (HIF-1α) Synthesis: Novel Mechanism for HIF-1-Mediated Vascular Endothelial Growth Factor Expression , 2001, Molecular and Cellular Biology.

[111]  D. Scudiero,et al.  Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway. , 2002, Cancer research.

[112]  M. Jaye,et al.  Gene expression of fibroblast growth factors in human gliomas and meningiomas: demonstration of cellular source of basic fibroblast growth factor mRNA and peptide in tumor tissues. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[113]  A. Tomida,et al.  Dephosphorylated hypoxia-inducible factor 1α as a mediator of p53-dependent apoptosis during hypoxia , 2001, Oncogene.

[114]  A. Giaccia,et al.  Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. , 1996, Cancer research.

[115]  A. Giaccia,et al.  Hypoxia Links ATR and p53 through Replication Arrest , 2002, Molecular and Cellular Biology.

[116]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[117]  J. Folkman,et al.  Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[118]  C. Heldin,et al.  Platelet‐derived growth factor in human glioma , 1995, Glia.

[119]  G. Semenza,et al.  HIF-1 and human disease: one highly involved factor. , 2000, Genes & development.

[120]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[121]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[122]  G. Reifenberger,et al.  Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. , 1993, Cancer research.

[123]  Erwin G. Van Meir,et al.  Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. , 2002, Cancer research.